Profound Medical (NASDAQ:PROF; TSX:PRN) and GE Healthcare agreed to a non-exclusive, worldwide license that will enable Profound to interface its TULSA-PRO system with certain GE Healthcare MRI scanners.
The collaboration with GE Healthcare expands Profound’s potential to interface with a significant portion of GE’s new and currently installed MRI scanners globally. TULSA-PRO is already compatible with certain MRI scanners manufactured by Philips and Siemens.
TULSA-PRO is a transurethral prostate tissue ablation system that combines real-time MRI with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue.
Citing the potential to expand the portfolio of MRI scanners that support TULSA-PRO technology, Arun Menawat, CEO and chairman of Profound, said in a statement that the addition of GE Healthcare gives Profound’s customers the maximum flexibility to use the MRI hardware of their choice.
“We are grateful to our existing customers who have embraced TULSA-PRO and look forward to making the benefits of this technology even more widely available,” he added.
Baldev Ahluwalia, GE MR Beyond segment general manager, said Profound’s exciting non-invasive therapy technology has the potential to bring significant benefit to a large number of prostate cancer patients.
“GE Healthcare has a long history of applying MR to therapy guidance and control; we are pleased to add TULSA-PRO capabilities to provide our customers with more options to treat their patients,” he added.